Cargando…

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas

In patients with glioblastoma, antiangiogenic therapy with bevacizumab (BEV) has been shown to improve progression-free survival (PFS), but not overall survival (OS). Especially in patients with an unusual infiltrative phenotype as seen in multifocal glioblastoma, the use of BEV therapy is still mor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burger, Michael C., Breuer, Stella, Cieplik, Hans C., Harter, Patrick N., Franz, Kea, Bähr, Oliver, Steinbach, Joachim P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713435/ https://www.ncbi.nlm.nih.gov/pubmed/29156610 http://dx.doi.org/10.3390/ijms18112469

Ejemplares similares

Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases
por: Burger, Michael C., et al.
Publicado: (2018)

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern
por: Burger, Michael C., et al.
Publicado: (2017)

ERGO: A pilot study of ketogenic diet in recurrent glioblastoma
por: RIEGER, JOHANNES, et al.
Publicado: (2014)

Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A (1)H-Magnetic Resonance Spectroscopy Study
por: Steidl, Eike, et al.
Publicado: (2016)

Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma
por: Thiepold, Anna-Luisa, et al.
Publicado: (2015)

Phospholipid Metabolites in Recurrent Glioblastoma: In Vivo Markers Detect Different Tumor Phenotypes before and under Antiangiogenic Therapy
por: Hattingen, Elke, et al.
Publicado: (2013)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
por: Fack, Fred, et al.
Publicado: (2014)

Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma
por: Scholz, Alexander, et al.
Publicado: (2015)

Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma
por: Divé, Iris, et al.
Publicado: (2023)

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
por: Reardon, David A., et al.
Publicado: (2020)

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
por: Burger, Michael C., et al.
Publicado: (2019)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
por: Niyazi, Maximilian, et al.
Publicado: (2015)

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
por: Burger, Michael C., et al.
Publicado: (2017)

Survival and recurrence patterns of multifocal glioblastoma after radiation therapy
por: Syed, Mustafa, et al.
Publicado: (2018)

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
por: Nagpal, Seema, et al.
Publicado: (2011)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Non-Invasive Measurement of Drug and 2-HG Signals Using (19)F and (1)H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032
por: Wenger, Katharina J., et al.
Publicado: (2020)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors
por: Bähr, Oliver, et al.
Publicado: (2017)

Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma
por: Georgescu, Maria-Magdalena, et al.
Publicado: (2020)

Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors
por: Burger, Michael C., et al.
Publicado: (2016)

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma
por: Urup, Thomas, et al.
Publicado: (2020)

Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
por: You, Weir-Chiang, et al.
Publicado: (2023)

Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
por: Almubarak, Mohammed, et al.
Publicado: (2008)

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
por: Zeiner, Pia S., et al.
Publicado: (2019)

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2018)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

“Paradoxical” findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab
por: Yamamoto, Yohei, et al.
Publicado: (2017)

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Omar, Ayman I.
Publicado: (2014)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
por: Choi, Seung Won, et al.
Publicado: (2018)

Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma
por: Vaios, Eugene J, et al.
Publicado: (2020)

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
por: Fu, Minjie, et al.
Publicado: (2023)

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
por: Cloughesy, Timothy F, et al.
Publicado: (2020)

Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence
por: Christ, Sebastian M., et al.
Publicado: (2023)

Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
por: Desjardins, Annick, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6hhudh5u0ml8v49niob9kpuq21